Therapeutic flag Cosmetic cross-reference

Lysine

CAS 56-87-1

Lysine (CAS 56-87-1) is a Phase 2 pharmaceutical compound with 1 bioactivity target and 72 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral / FAERS

Adverse signals

SOURCE IUPHAR / PharmGKB

PubMed IDs

SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Lysine

CAS Number

56-87-1

UNII

K3Z4F929H6

InChIKey

KDXKERNSBIXSRK-YFKPBYRVSA-N

ChEMBL ID

CHEMBL8085

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

Synonyms and normalized names

L-lysine

natural producttherapeutic flag

SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2

Mid-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL8085 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE ChEMBL 36 activities + assays 5 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Kd	1664 nM	5	-
-	IC50	63100 nM	2	-
-	Ki	54600 nM	1	-
-	Potency	141.3 nM	1	-
Glutathione reductase, mitochondrial Enzyme	Ki	4.26	-	Homo sapiens

SOURCE DrugCentral 2023 / FAERS disproportionality 11 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Foetal growth restriction	17	39.155	10070531
Infantile apnoea	8	27.087	10077321
Vasoplegia syndrome	9	27.028	10067080
Compartment syndrome	9	24.147	10010121
Sinusitis	41	22.588	10040753
Selective eating disorder	8	22.498	10078069
Fatigue	106	19.329	10016256
Coma scale abnormal	9	19.3	10069709
Headache	78	18.882	10019211
Pulse absent	9	18.046	10037469
Cerebral haemorrhage	18	18.029	10008111

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR ligand-target interactions 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
GPRC6 GPRC6A	Full agonist	3.8 pEC50	15576628

SOURCE RxNorm drug names 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
LYSINE	6536	SU	MTHSPL
lysine	6536	IN	RXNORM
L-lysine	6536	SY	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Lysine used for in pharmaceutical contexts?

Lysine (CAS 56-87-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Lysine?

Lysine has 72 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Foetal growth restriction, Infantile apnoea, Vasoplegia syndrome, Compartment syndrome, Sinusitis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Lysine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for L-Lysine with EU status "permitted".

What clinical phase is Lysine in?

Lysine is rendered with ChEMBL max phase 2.

What bioactivity targets are documented for Lysine?

Lysine has 5 bioactivity rows in this page query. Rendered target entries include Glutathione reductase, mitochondrial.